# Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)

> **NCT06959784** · PHASE4 · ENROLLING_BY_INVITATION · sponsor: **China-Japan Friendship Hospital** · enrollment: 142 (estimated)

## Conditions studied

- Diabetes Mellitus
- Cardiovascular Diseases
- Cerebrovascular Disease

## Interventions

- **DRUG:** semaglutide
- **DRUG:** Metformin

## Key facts

- **NCT ID:** NCT06959784
- **Lead sponsor:** China-Japan Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-01-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 142 (ESTIMATED)
- **Last updated:** 2025-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06959784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06959784, "Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06959784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*